Type
|
subsidiary of Merck KGaA |
---|---|
Traded as | NASDAQ: SIAL |
Industry | chemicals |
Founded | August 1975 |
Headquarters | St. Louis, Missouri United States |
Key people
|
Rakesh Sachdev (CEO) |
Products | life science technologies and specialty chemicals |
Revenue | US$ 2.7 billion (2014) |
Operating income
|
US$ 681.0 million (2014) |
Net income
|
US$ 500.0 million (2014) |
Total assets | US$ 4.19 billion (2014) |
Total equity | US$ 3.13 billion (2014) |
Number of employees
|
more than 9,600 |
Parent | Merck KGaA (100%) |
Website | www |
Sigma-Aldrich Corporation is an American chemical, life science and biotechnology company owned by Merck KGaA.
Created by the 1975 merger of Sigma Chemical Company and Aldrich Chemical Company, Sigma-Aldrich since grew through various acquisitions until it had over 9,600 employees and was listed on the Fortune 1000 at the time of its acquisition by Merck. The company is headquartered in St. Louis and has operations in approximately 40 countries.
In September 2014, the German company Merck KGaA announced that it would be acquiring Sigma-Aldrich for $17 billion USD. The acquisition was completed in November 2015 and Sigma-Aldrich became a subsidiary of Merck KGaA. The company is currently a part of Merck's life science business and in combination with Merck's earlier acquired Millipore, operates as MilliporeSigma.
Sigma Chemical Company of St Louis and Aldrich Chemical Company of Milwaukee were both American specialty chemical companies when they merged in August 1975. The company grew throughout the '80s and '90s, with significant expansion in facilities, acquisitions and diversification into new market sectors.
Key numbers for Sigma-Aldrich.
Revenues:
Products:
Customers:
Geographies (% of 2008 sales):
The company is divided into four business units, for which separate financial performance data are reported:
Aldrich is a supplier in the research and fine chemicals market. Aldrich provides organic and inorganic chemicals, building blocks, reagents, advanced materials and stable isotopes for chemical synthesis, medicinal chemistry and materials science. Aldrich's chemicals catalog, the "Aldrich Catalog and Handbook" is often used as a handbook due to the inclusion of structures, physical data, and literature references.
Sigma is the Sigma-Aldrich's main biochemical supplier, with offerings including antibiotics, buffers, carbohydrates, enzymes, forensic tools, hematology and histology, nucleotides, proteins, peptides, amino acids and their derivatives.
Sigma RBI produces specialized products for use in the field of cell signaling and neuroscience. Their offerings range from standard biochemical reagents to specialized research tools, including ligands for receptors and ion channels, enzyme inhibitors, phosphospecific antibodies, key signal transduction enzymes, and assay kits for cell signaling.
ISOTEC provides isotopically labeled products for protein structure determination, peptide synthesis, proteomics, metabolic research, magnetic resonance imaging, nuclear magnetic resonance, breath test substrates, agriculture, as well as gas and gas mixes.
Fluka manufactures chemicals and reagents for analytical, organic and biochemical research, and intermediates for the chemical and pharmaceutical industries.
Riedel-de Haën was incorporated with Sigma-Aldrich in 1999 and manufactures reagents and standards.
Supelco is the chromatography products branch of Sigma-Aldrich. It provides chromatography columns and related tools for environmental, government, food and beverage, pharmaceutical, biotechnology, medical and chemical laboratories; sample preparation products and chemical reference standards.
Sigma-Aldrich Fine Chemicals (SAFC) is the fine chemical supply branch of Sigma-Aldrich specializing in raw materials for cell culture products; customized services for raw materials, manufacturing of active pharmaceutical ingredients.
Sigma Life Science provides products such as custom DNA/RNA oligos; custom DNA and LNA probes; siRNA; isotopically-labelled peptides and peptide libraries.
Sigma Advanced Genetic Engineering (SAGE) Labs is a division within Sigma-Aldrich that specializes in genetic manipulation of in vivo systems for special research and development applications. It was formed in 2008 to investigate zinc finger nuclease technology and its application for disease research models. Located in St. Louis, Missouri, SAGE Labs have developed knockout rats for the study of human diseases and disorders (such as autism), which are sold for up to US$95,000. SAGE also announced its first successful effort in creating a "knockout rabbit". Its facilities include a specific pathogen free, biosecure vivarium as well as research and development labs.
Carbolabs produces research quantities of chemicals produced by phosgenation reactions. The company was acquired in 1998.
BioReliance provides testing and manufacturing services to pharmaceutical and biopharmaceutical companies that span the product cycle from early pre-clinical development to licensed production. The company was acquired by Sigma Aldrich in January 2012.
Sigma-Aldrich is located in 40 countries world-wide. In territories where they are not present, Sigma-Aldrich operates through a network of authorized distributors. A list of them can be found below:
The company also operates an eCommerce platform "which offers 24-hour delivery in major markets."
Sigma-Aldrich has been recognized for its commitment to the community and environment numerous times:
Media related to Sigma-Aldrich at Wikimedia Commons
2014-09-23 | Downgrade | KeyBanc | Buy to Hold | $112.00 |
2014-09-23 | Downgrade | KeyCorp | Buy to Hold | $112.00 |
2014-09-22 | Upgrade | Goldman Sachs | Sell to Neutral | |
2014-09-22 | Boost Price Target | MKM Partners | Buy | $95.00 to $140.00 |
2014-09-22 | Upgrade | Goldman Sachs Group Inc. | Sell to Neutral | |
2014-07-25 | Reiterated Rating | JPMorgan Chase & Co. | Neutral | $95.00 to $97.00 |
2014-07-17 | Initiated Coverage | Citigroup Inc. | Neutral | $107.00 |
2014-07-16 | Reiterated Rating | KeyBanc | Buy | $108.00 to $112.00 |
2014-04-25 | Reiterated Rating | JPMorgan Chase & Co. | Neutral | $95.00 |
2014-04-25 | Boost Price Target | Mizuho | Neutral | $85.00 to $95.00 |
2014-02-21 | Downgrade | Edward Jones | Buy to Hold | |
2013-12-27 | Boost Price Target | KeyBanc | $104.00 | |
2013-10-23 | Boost Price Target | Jefferies Group | Hold | $71.00 to $78.00 |
2013-10-22 | Boost Price Target | Mizuho | Neutral | $80.00 to $85.00 |
2013-10-17 | Initiated Coverage | Morgan Stanley | Underweight | $82.00 |
2013-09-27 | Boost Price Target | Goldman Sachs | Sell | $69.00 to $73.00 |
2013-09-20 | Downgrade | Robert W. Baird | Outperform to Neutral | $80.00 |
2013-07-23 | Reiterated | Mizuho | Neutral | $75 to $80 |
2011-02-10 | Downgrade | Longbow | Buy to Neutral | |
2010-10-22 | Reiterated | Longbow | Buy | $65 to $72 |
2010-02-11 | Upgrade | Robert W. Baird | Neutral to Outperform | $60 |
2009-08-26 | Reiterated | KeyBanc Capital Mkts | Buy | $54 to $60 |
2009-04-24 | Reiterated | UBS | Neutral | $40 to $44 |
2009-02-04 | Downgrade | Longbow | Buy to Neutral | |
2008-12-15 | Reiterated | Robert W. Baird | Neutral | $46 to $40 |
2008-10-23 | Reiterated | Longbow | Buy | $75 to $50 |
2014-09-23 | Downgrade | KeyBanc | Buy to Hold | $112.00 |
2014-09-23 | Downgrade | KeyCorp | Buy to Hold | $112.00 |
2014-09-22 | Upgrade | Goldman Sachs | Sell to Neutral | |
2014-09-22 | Boost Price Target | MKM Partners | Buy | $95.00 to $140.00 |
2014-09-22 | Upgrade | Goldman Sachs Group Inc. | Sell to Neutral |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In SIAL 14 funds of 2213 total. Show all
Fund name | Ticker shares |
---|---|
Loeb Offshore Management LP | 0.14M |
BAIRD ROBERT W & CO INC /WI/ | 21675 |
Andromeda Capital LLC | 11838 |
CITY NATIONAL BANK | 4636 |
BOSTON PRIVATE BANK & TRUST CO | 4162 |
VTL Associates, LLC | 1692 |
Placemark Investments, Inc. | 1467 |
SHAPIRO ROBERT N | 847 |
GUARDIAN INVESTOR SERVICES LLC | 822 |
Index Management Solutions, LLC | 577 |
VALLEY NATIONAL BANCORP | 300 |
NEW ENGLAND SECURITIES CORP /MA/ | 241 |
MANAGED ACCOUNT ADVISORS LLC | 181 |
HABERER REGISTERED INVESTMENT ADVISOR INC | 39 |
Name Relationship | Total Shares | Holding stocks |
---|---|---|
Green Eric Mark EVP & President, Research | 0.02% (24964) | SIAL / WST / |